Our Parent Company

Established forty years ago, Wockhardt has evolved into one of India's top five research-based pharmaceutical companies and is amongst the top seventy-five in the world. The group now employs over 3,500 people globally.

Wockhardt's insight into evolving global markets has resulted in a dramatic increase in international business.

Shaping the Future

• A combination of cutting edge facilities and innovative process development techniques has resulted in a world-class pharmaceutical force.
  
  
• The Wockhardt facility supports a multidisciplinary research programme involved in biotechnology, super-generics and new chemical entities. Key research areas include bio-generics, antibacterials and nutrition. Wockhardt is the first company outside of the USA and Europe to manufacture recombinant insulin and the launch of hepatitis B vaccine was the most successful in Indian history.
  
  
• Investment in Research & Development has reached $43million in the last 5 years alone. Wockhardt’s policy is to maintain an annual R&D spend approaching 8% of sales, a figure on par with the world’s elite pharmaceutical companies.
  
  
• Wockhardt’s ambition is to refine and develop a global supply chain competence, offering a truly integrated service.

To find out more about Wockhardt, please visit www.wockhardt.com. Please note: The information available at this address is aimed at Wockhardt customers in India.